Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Percheron Therapeutics ( (AU:PER) ) has issued an announcement.
Percheron Therapeutics Limited announced the results of its General Meeting, where over 90% of shareholders voted to retain the current Board, rejecting nominees from Powerhouse Ventures Limited. This strong shareholder support allows the company to concentrate on its mission to restore value for shareholders and continue its focus on developing therapies for rare diseases.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for rare diseases. The company’s lead program, avicursen (ATL1102), is an antisense oligonucleotide targeting the CD49d receptor, investigated for inflammatory conditions like multiple sclerosis and Duchenne muscular dystrophy.
Technical Sentiment Signal: Sell
Current Market Cap: $7.6M
For an in-depth examination of PER stock, go to TipRanks’ Stock Analysis page.